Maze Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
During the three months ended March 31, 2026, the following directors and/or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” in each case as defined in Item 408 of Regulation S-K:
| Character of Trading Arrangement | ||||||
|---|---|---|---|---|---|---|
| Action · Date of · Rule · Non-Rule · Nature of · Aggregate Number · Duration of Trading | ||||||
| Name and Title · Taken · Action · 10b5-1* · 10b5-1** · Trading · of Securities · Arrangement(1) | ||||||
| Jason Coloma, Chief Executive Officer and Director | Adopted | February 6, 2026 | X | Sale | 414,012 | 5/15/2026-5/15/2027 |
| *Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. | ||||||
| **"Non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K under the Exchange Act. | ||||||
| 1 The trading arrangement may expire on an earlier date if and when all transactions under the arrangement are completed. | ||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.